P.E. Yanez Weber

VP1-2023: Pembrolizumab (pembro) plus chemotherapy (chemo) as first-line therapy for advanced HER2-negative gastric or gastroesophageal junction (G/GEJ) cancer: Phase III KEYNOTE-859 study

Sun Young Rha, L.S. Wyrwicz, P.E. Yanez Weber et al. · Annals of Oncology · 2023 · 66 citations · Full text

Medicine, Oncology, Pharmacology +13

1400O Final overall survival for the phase III, KEYNOTE-811 study of pembrolizumab plus trastuzumab and chemotherapy for HER2+ advanced, unresectable or metastatic G/GEJ adenocarcinoma

Y. Y. Janjigian, Akihito Kawazoe, Yikui Bai et al. · Annals of Oncology · 2024 · 38 citations · Full text

Medicine, Oncology, Pharmacology +17

LBA74 Pembrolizumab plus chemotherapy vs chemotherapy as neoadjuvant and adjuvant therapy in locally-advanced gastric and gastroesophageal junction cancer: The phase III KEYNOTE-585 study

Kohei Shitara, Sun Young Rha, Lucjan Wyrwicz et al. · Annals of Oncology · 2023 · 34 citations · Full text

Medicine, Oncology, Pharmacology +15

Pembrolizumab Plus Chemotherapy Versus Chemotherapy as Perioperative Therapy in Locally Advanced Gastric and Gastroesophageal Junction Cancer: Final Analysis of the Randomized, Phase III KEYNOTE-585 Study

Sun Young Rha, Lucjan Wyrwicz, Nina Karaseva et al. · Journal of Clinical Oncology · 2025 · 29 citations

Medicine, Oncology, Perioperative Medicine +17

LBA3 Final analysis of the phase III KEYNOTE-585 study of pembrolizumab plus chemotherapy vs chemotherapy as perioperative therapy in locally-advanced gastric and gastroesophageal junction cancer

Kohei Shitara, Sun Young Rha, Lucjan Wyrwicz et al. · Annals of Oncology · 2024 · 13 citations · Full text

Medicine, Oncology, Perioperative Medicine +13